Some recent FDA approvals have made many people aware of tumor-agnostic treatments. But what does that mean and how could it benefit someone with cancer? ASCO Chief Medical Officer Richard L. Schilsky gives insight into this new way of thinking about cancer treatment.
Kidney cancer is the sixth most common cancer for men and the tenth most common cancer for women. Cancer.Net Associate Editor Brian Rini, MD, shares 4 things people need to know about kidney cancer.
Lung cancer affects tens of thousands of Americans every year. In this blog post, Cancer.Net Associate Editor Dr. Jyoti Patel describes 9 things every person should know about lung cancer.
In this podcast, Dr. Gary Lyman describes biosimilars for cancer treatment and why they are important. He also talks about why ASCO is releasing a statement on them today.
ASCO and NCCN have worked together to help clinicians and patients identify and treat the side effects of immunotherapy before they become dangerous. Doctor and patient advocate Laura Porter describes what to watch out for if you’re taking an immune checkpoint inhibitor, a type of immunotherapy, for cancer.
The 2018 Clinical Cancer Advances report of the American Society of Clinical Oncology has crowned an adoptive cell immunotherapy as its Advance of the Year. What is this innovative cancer treatment? What are the risks and benefits?
“Even after I heard horror stories about the negative effects of indoor tanning, I knew they’d never happen to me. I couldn’t have been more wrong.” Ashley Drury shares her journey from tanning bed advocate to survivor of advanced melanoma.
In this month’s From the Editor’s Desk, Dr. Schapira reviews highlights of 2017 in the world of cancer treatment and care.
Cancer survivor Bryant Wieneke describes his experience receiving immunotherapy to treat metastatic melanoma.
La inmunoterapia ha hecho avances apasionantes en 2015. Dado su potencial, ASCO la nombró el adelanto clínico del año 2016 para el cáncer.